Rapid DNA Analysis Market Research Report – Segmentation by Technology (PCR, Microarray, and Next-generation sequencing); By Application (Cancer genetics tests and Newborn genetics screening); By End-user (Critical military, forensic, homeland security, and Biomedical Research); Region – Size, Share, Growth Analysis |Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16062
Format:
Region: Global
Chapter 1. Global Rapid DNA Analysis Market – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Rapid DNA Analysis Market – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. Global Rapid DNA Analysis Market – Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. Global Rapid DNA Analysis Market - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Rapid DNA Analysis Market - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Rapid DNA Analysis Market – By Technology
6.1. PCR
6.2. Microarray
6.3. Next-Generation Sequencing
Chapter 7. Global Rapid DNA Analysis Market – By Application
-
- Cancer genetics tests
- Newborn Genetic Screening
Chapter 8. Global Rapid DNA Analysis Market – By End User
8.1. Critical Military
8.2. Forensic
8.3. Security
8..4. Biomedical Research
Chapter 9. Global Rapid DNA Analysis Market, By Geography – Market Size, Forecast, Trends & Insights
9.1. North America
9.1.1. By Country
9.1.1.1. U.S.A.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. By Technology
9.1.3. By Application
9.1.4. By End User
9.1.5. Countries & Segments - Market Attractiveness Analysis
9.2. Europe
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Germany
9.2.1.3. France
9.2.1.4. Italy
9.2.1.5. Spain
9.2.1.6. Rest of Europe
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End User
9.2.5. Countries & Segments - Market Attractiveness Analysis
9.3. Asia Pacific
9.3.2. By Country
9.3.2.2. China
9.3.2.2. Japan
9.3.2.3. South Korea
9.3.2.4. India
9.3.2.5. Australia & New Zealand
9.3.2.6. Rest of Asia-Pacific
9.3.2. By Technology
9.3.3. By Application
9.3.4. By End User
9.3.5. Countries & Segments - Market Attractiveness Analysis
9.4. South America
9.4.3. By Country
9.4.3.3. Brazil
9.4.3.2. Argentina
9.4.3.3. Colombia
9.4.3.4. Chile
9.4.3.5. Rest of South America
9.4.2. By Technology
9.4.3. By Application
9.4.4. By End User
9.4.5. Countries & Segments - Market Attractiveness Analysis
9.5. Middle East & Africa
9.5.4. By Country
9.5.4.4. United Arab Emirates (UAE)
9.5.4.2. Saudi Arabia
9.5.4.3. Qatar
9.5.4.4. Israel
9.5.4.5. South Africa
9.5.4.6. Nigeria
9.5.4.7. Kenya
9.5.4.8. Egypt
9.5.4.9. Rest of MEA
9.5.2. By Technology
9.5.3. By Application
9.5.4. By End User
9.5.5. Countries & Segments - Market Attractiveness Analysis
Chapter 10. Global Rapid DNA Analysis Market – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1. Thermo Fisher Scientific Inc.
10.2. Illumina Inc.
10.3. Rapidhit
10.4. ANDE Corporation
10.5. IntegenX Inc.
10.6. General Electric Company
10.7. DNASwift
10.8. Universal Forensics Laboratory
10.9. Micropia
10.10. Abbott Medical Optics Inc.
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Rapid DNA Analysis Market was valued at USD 14.03 billion in 2023.
Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 4%.
The driving factors are the growing need for prenatal and newborn screenings and the growing use of personalized medicine applications in the management of chronic illnesses.
The market restraint is the high development costs of these diagnostic tests.
Cancer genetics tests and Newborn Genetic Screening are the segments according to applications.
